Antimicrobial resistance (AMR) is a critical global health challenge as infections are increasingly difficult to treat due to resistant bacteria. P. aeruginosa is a World Health Organization priority pathogen associated with severe hospital-acquired infections with high levels of resistance. There is a global unmet need to improve the way we treat bacterial infections.
Virulence factors are the weapon systems bacteria use to cause disease. Our small molecule specifically targets swarming, a key virulence factor of P. aeruginosa. This approach not only prevents infection from taking hold but works synergistically with antibiotics to enhance their efficacy in treating acute infections.
Company Details
- Employees
- 2
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- South San Francisco.
Veirulence Ltd Questions
Veirulence Ltd's LinkedIn profile is https://www.linkedin.com/company/veirulence-ltd
Veirulence Ltd has
2 employees.
View email and phone details for 2
employees at Veirulence Ltd.
Veirulence Ltd's industry is
Biotechnology Research
Veirulence Ltd's top competitors are
Mycobiologics Ltd,
Druid Health,
M&f Tech,
Blue Matter,
Healx,
M3dicube,
Biorevert Inc.,
Qib Extra,
Oms Technologies,
Aridom Sanex.
Veirulence Ltd's categories are Biotechnology Research
